Our work also demonstrates the potential of DYRK1A inhibitors as sleep correctors for DS and AD-DS which may slow pathology and boost cognition, the high throughput capability of flies will allow further characterisation and screening of DS and AD circadian and sleep drugs (Dissel et al., 2017; Wang et al., 2020). The gene discussed is DYRK1A; the disease is Alzheimer disease.